Could Repros Therapeutics Inc (RPRX) Gain Strenght? The Stock Reaches 52-Week Low

July 17, 2017 - By Winifred Garcia

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.20, from 1.08 in 2016Q3. It is negative, as 8 investors sold Repros Therapeutics Inc shares while 8 reduced holdings. 4 funds opened positions while 10 raised stakes. 6.56 million shares or 1.15% more from 6.48 million shares in 2016Q3 were reported.
Moreover, Riverpoint Cap Mngmt Ltd Liability Company has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 11,000 shares. Blackrock Invest Management Ltd Liability Company invested in 0% or 3,757 shares. Wells Fargo Mn has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 5,400 shares. Kcg Inc accumulated 0% or 45,144 shares. Blackrock Advsr Llc reported 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Northern Tru has 72,672 shares for 0% of their portfolio. Prelude Capital Mgmt Limited Liability reported 0% in Repros Therapeutics Inc (NASDAQ:RPRX). The Massachusetts-based Baldwin Brothers Ma has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Manufacturers Life Commerce The invested in 1,321 shares. Blackrock Institutional Trust Na owns 700,608 shares. Geode Capital Management Ltd Co holds 133,328 shares. National Bank & Trust Of New York Mellon Corporation has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). General American Investors Incorporated holds 589,768 shares. Barclays Public Ltd Com has invested 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX). Blackrock Fund holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 60,822 shares.

The stock of Repros Therapeutics Inc (NASDAQ:RPRX) hit a new 52-week low and has $0.36 target or 3.00 % below today’s $0.37 share price. The 9 months bearish chart indicates high risk for the $10.88M company. The 1-year low was reported on Jul, 17 by Barchart.com. If the $0.36 price target is reached, the company will be worth $326,400 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 5.58 million shares traded or 452.48% up from the average. Repros Therapeutics Inc (NASDAQ:RPRX) has declined 73.82% since July 17, 2016 and is downtrending. It has underperformed by 90.52% the S&P500.

Repros Therapeutics Inc (NASDAQ:RPRX) Ratings Coverage

Among 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Repros Therapeutics had 5 analyst reports since August 20, 2015 according to SRatingsIntel. Bank of America downgraded Repros Therapeutics Inc (NASDAQ:RPRX) on Friday, October 30 to “Underperform” rating. As per Friday, October 30, the company rating was downgraded by Brean Capital. The rating was upgraded by Ladenburg Thalmann on Wednesday, November 16 to “Buy”. On Thursday, August 20 the stock rating was upgraded by Zacks to “Hold”. The rating was downgraded by Ladenburg Thalmann to “Neutral” on Friday, October 30.

More notable recent Repros Therapeutics Inc (NASDAQ:RPRX) news were published by: Nasdaq.com which released: “BUZZ-US STOCKS ON THE MOVE-Snap, Repros, Sprint, BlackRock” on July 17, 2017, also Globenewswire.com with their article: “Repros Names Larry Dillaha, MD, its Permanent President and CEO” published on April 10, 2017, Globenewswire.com published: “Repros Announces Proposed Public Offering Of Common Stock And Warrants To …” on May 17, 2017. More interesting news about Repros Therapeutics Inc (NASDAQ:RPRX) were released by: Streetinsider.com and their article: “Form 8-K REPROS THERAPEUTICS INC. For: Jul 17” published on July 17, 2017 as well as Globenewswire.com‘s news article titled: “Repros Announces the Issuance of New US Patent Relating to Treatment Using Off …” with publication date: April 17, 2017.

Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has market cap of $10.88 million. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. It currently has negative earnings. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: